JP2023171614A5 - - Google Patents

Download PDF

Info

Publication number
JP2023171614A5
JP2023171614A5 JP2023176883A JP2023176883A JP2023171614A5 JP 2023171614 A5 JP2023171614 A5 JP 2023171614A5 JP 2023176883 A JP2023176883 A JP 2023176883A JP 2023176883 A JP2023176883 A JP 2023176883A JP 2023171614 A5 JP2023171614 A5 JP 2023171614A5
Authority
JP
Japan
Prior art keywords
oral formulation
subject
administered
oral
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023176883A
Other languages
English (en)
Japanese (ja)
Other versions
JP7688681B2 (ja
JP2023171614A (ja
Filing date
Publication date
Priority claimed from JP2018567299A external-priority patent/JP6895464B2/ja
Application filed filed Critical
Publication of JP2023171614A publication Critical patent/JP2023171614A/ja
Publication of JP2023171614A5 publication Critical patent/JP2023171614A5/ja
Priority to JP2025086125A priority Critical patent/JP2025124733A/ja
Application granted granted Critical
Publication of JP7688681B2 publication Critical patent/JP7688681B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023176883A 2016-06-21 2023-10-12 アルドース還元酵素阻害剤およびその使用方法 Active JP7688681B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025086125A JP2025124733A (ja) 2016-06-21 2025-05-23 アルドース還元酵素阻害剤およびその使用方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662352784P 2016-06-21 2016-06-21
US62/352,784 2016-06-21
JP2018567299A JP6895464B2 (ja) 2016-06-21 2017-06-21 アルドース還元酵素阻害剤およびその使用方法
JP2021094883A JP7368419B2 (ja) 2016-06-21 2021-06-07 アルドース還元酵素阻害剤およびその使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021094883A Division JP7368419B2 (ja) 2016-06-21 2021-06-07 アルドース還元酵素阻害剤およびその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025086125A Division JP2025124733A (ja) 2016-06-21 2025-05-23 アルドース還元酵素阻害剤およびその使用方法

Publications (3)

Publication Number Publication Date
JP2023171614A JP2023171614A (ja) 2023-12-01
JP2023171614A5 true JP2023171614A5 (cg-RX-API-DMAC10.html) 2023-12-08
JP7688681B2 JP7688681B2 (ja) 2025-06-04

Family

ID=60783884

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018567299A Active JP6895464B2 (ja) 2016-06-21 2017-06-21 アルドース還元酵素阻害剤およびその使用方法
JP2021094883A Active JP7368419B2 (ja) 2016-06-21 2021-06-07 アルドース還元酵素阻害剤およびその使用方法
JP2023176883A Active JP7688681B2 (ja) 2016-06-21 2023-10-12 アルドース還元酵素阻害剤およびその使用方法
JP2025086125A Pending JP2025124733A (ja) 2016-06-21 2025-05-23 アルドース還元酵素阻害剤およびその使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018567299A Active JP6895464B2 (ja) 2016-06-21 2017-06-21 アルドース還元酵素阻害剤およびその使用方法
JP2021094883A Active JP7368419B2 (ja) 2016-06-21 2021-06-07 アルドース還元酵素阻害剤およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025086125A Pending JP2025124733A (ja) 2016-06-21 2025-05-23 アルドース還元酵素阻害剤およびその使用方法

Country Status (21)

Country Link
US (6) US10150779B2 (cg-RX-API-DMAC10.html)
EP (3) EP3352754B1 (cg-RX-API-DMAC10.html)
JP (4) JP6895464B2 (cg-RX-API-DMAC10.html)
CN (2) CN109310674B (cg-RX-API-DMAC10.html)
AU (4) AU2017281082B2 (cg-RX-API-DMAC10.html)
CA (1) CA3025081A1 (cg-RX-API-DMAC10.html)
DK (2) DK3352754T3 (cg-RX-API-DMAC10.html)
ES (2) ES2966094T3 (cg-RX-API-DMAC10.html)
FI (1) FI3757107T3 (cg-RX-API-DMAC10.html)
HR (2) HRP20231563T1 (cg-RX-API-DMAC10.html)
HU (2) HUE052101T2 (cg-RX-API-DMAC10.html)
IL (3) IL283809B2 (cg-RX-API-DMAC10.html)
LT (2) LT3757107T (cg-RX-API-DMAC10.html)
MX (2) MX391561B (cg-RX-API-DMAC10.html)
PL (1) PL3757107T3 (cg-RX-API-DMAC10.html)
PT (2) PT3352754T (cg-RX-API-DMAC10.html)
RS (1) RS61239B1 (cg-RX-API-DMAC10.html)
SG (2) SG11201810642XA (cg-RX-API-DMAC10.html)
SI (2) SI3757107T1 (cg-RX-API-DMAC10.html)
WO (1) WO2017223179A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201808506B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12653825B2 (en) 2010-07-16 2026-06-16 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
ES2966094T3 (es) * 2016-06-21 2024-04-18 Univ Columbia Compuestos 4-oxo-3,4-dihidrotieno[3,4-d]piridazina como inhibidores de la aldosa reductasa y métodos de uso de los mismos
IL272246B2 (en) * 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
WO2020167937A1 (en) * 2019-02-12 2020-08-20 Applied Therapeutics, Inc. Methods for treating cutaneous aging
CN113840825A (zh) 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂
MX2021013511A (es) 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.
EP4041219A4 (en) * 2019-10-08 2023-11-01 Applied Therapeutics, Inc. ALDOSE REDUCTASE INHIBITORS FOR THE TREATMENT OF PHOSPHOMANNOMUTASE-2 DEFICIENCY
WO2021202523A1 (en) 2020-03-31 2021-10-07 Applied Therapeutics, Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
KR20230005944A (ko) * 2020-05-01 2023-01-10 어플라이드 테라퓨틱스 인크. 소르비톨 데히드로게나제 결핍 치료를 위한 알도스 리덕타제 억제제
US20240033263A1 (en) * 2021-03-18 2024-02-01 Banavara MYLARI Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications
WO2025219948A1 (en) 2024-04-17 2025-10-23 Assia Chemical Industries Ltd. Crystalline forms of govorestat

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0189272A3 (en) * 1985-01-17 1987-08-19 Fujisawa Pharmaceutical Co., Ltd. New furanone derivatives, processes for preparation thereof and use thereof
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
IL80475A (en) 1985-11-07 1993-01-31 Pfizer Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them
CA1299178C (en) 1985-11-07 1992-04-21 Banavara Lakshmana Mylari Heterocyclic oxophtalazinyl acetic acids
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
WO1989006651A1 (en) * 1988-01-19 1989-07-27 Pfizer Inc. 1h-indazole-3-acetic acids as aldose reductase inhibitors
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
US4954629A (en) 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
FI922308L (fi) 1989-12-15 1992-05-21 Pfizer Substituerade oxoftalazinylaettiks- syror och deras analoger.
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
WO1994007867A1 (en) * 1992-09-28 1994-04-14 Pfizer Inc. Substituted pyrimidines for control of diabetic complications
CN1200106A (zh) 1995-08-28 1998-11-25 美国家用产品公司 苯氧基乙酸类化合物用作醛糖还原酶抑制剂和抗高血糖药
US6169087B1 (en) 1997-09-23 2001-01-02 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPases)
AP2000001929A0 (en) 1998-03-31 2000-09-30 Inst For Pharm Discovery Inc Substituted indolealkanoic acids.
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
GEP20053675B (en) 2001-03-30 2005-11-25 Pfizer Prod Inc Pyridazinone Aldose Reductase Inhibitors
EP1469851B1 (en) 2002-01-23 2006-10-11 Eli Lilly And Company Melanocortin receptor agonists
WO2003105864A1 (en) 2002-06-13 2003-12-24 Board Of Regents, The University Of Texas System Methods and compositions involving aldose reductase inhibitors
EP1514870A4 (en) * 2002-06-14 2006-08-23 Takeda Pharmaceutical PRODRUG AND METHOD FOR THE PRODUCTION THEREOF
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
US20070021366A1 (en) 2004-11-19 2007-01-25 Srivastava Satish K Structural-based inhibitors of the glutathione binding site in aldose reductase, methods of screening therefor and methods of use
WO2006078717A2 (en) 2005-01-19 2006-07-27 Beth Israel Deaconess Medical Center Lipocalin 2 for the treatment, prevention, and management of cancer metastasis, angiogenesis, and fibrosis
CN101143868A (zh) 2007-09-04 2008-03-19 北京理工大学 醛糖还原酶抑制剂结构及用途
HUE031506T2 (en) * 2010-07-16 2017-07-28 Univ Columbia Aldose reductase inhibitors and their use
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
CN102512407B (zh) 2011-11-23 2014-05-21 中山大学 一种β-苯丙氨酸类化合物作为醛糖还原酶抑制剂的应用
ES2966094T3 (es) * 2016-06-21 2024-04-18 Univ Columbia Compuestos 4-oxo-3,4-dihidrotieno[3,4-d]piridazina como inhibidores de la aldosa reductasa y métodos de uso de los mismos
US11329472B2 (en) 2018-07-20 2022-05-10 Texas Instruments Incorporated Methods and apparatus to prevent undesired triggering of short circuit or over current protection

Similar Documents

Publication Publication Date Title
JP2021063088A5 (cg-RX-API-DMAC10.html)
JP2004527525A5 (cg-RX-API-DMAC10.html)
YU88901A (sh) Derivati purina
CA2443089A1 (en) Antifungal suspension of micronized posaconazole
JP2005526107A5 (cg-RX-API-DMAC10.html)
CA2671904A1 (en) Intermediate duration neuromuscular blocking agents and antagonists thereof
JP2005531607A5 (cg-RX-API-DMAC10.html)
PL187085B1 (pl) Preparat farmaceutyczny do leczenia i/lub zapobiegania zakażeniom HIV
AR036127A1 (es) Composicion para administracion topica que comprende un inhibidor de interleucina 2 y un agente antimicrobiano y uso de estos ultimos para preparar dicha composicion
RU2012113844A (ru) Пероральные суспензионные лекарственные формы ацетата эсликарбазепина
JP2022516099A5 (cg-RX-API-DMAC10.html)
HUP0303315A2 (hu) Pirazolo [4,3-d] pirimidineket és trombózisellenes szereket, kalcium antagonistákat, prosztaglandinokat vagy prosztaglandinszármazékokat tartalmazó gyógyszerkészítmények
JP2634202B2 (ja) 抗ウイルス性化合物
ITRM20000667A1 (it) Compressa matrice che permette la liberazione prolungata di trimetazidina dopo somministrazione per via orale.
JP2013535472A5 (cg-RX-API-DMAC10.html)
JP2024544538A5 (cg-RX-API-DMAC10.html)
JP2590156B2 (ja) 経口投与用医薬組成物
RU2008146217A (ru) Фармацевтическая композиция, содержащая производное таксана, которая предназначена для приготовления инфузионного раствора, способ его приготовления и использование
RU2019137020A (ru) Составы со сниженным окислением
EP4205742A1 (en) Composition for treating coronavirus-19 infection, comprising phenanthroindolizidine and phenanthroquinolizidine alkaloid derivative, optical isomer thereof, or pharmaceutically acceptable salt thereof as active ingredient
JP2022520410A5 (cg-RX-API-DMAC10.html)
JP4737911B2 (ja) 点眼剤
IE912237A1 (en) Pharmaceutical preparations
IL160082A0 (en) Quinoline derivatives and use thereof as antitumor agents
JP2007525533A5 (cg-RX-API-DMAC10.html)